翰森制药:HS-10374治疗中重度斑块状银屑病III期临床研究达共同主要终点

南方财经网
Sep 21

南财智讯9月21日电,翰森制药(03692.HK)发布自愿公告,公司自研酪氨酸激酶2(TYK2)选择性变构抑制剂HS-10374,在用于成人中重度斑块状银屑病的关键性III期临床试验中达到共同主要终点:在治疗第16周,HS-10374组达到银屑病面积和严重程度指数(PASI)较基线下降至少75%(PASI75)的患者比例,以及达到静态医师整体评估(sPGA)评分0或1且较基线降低至少2分(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10